PLIANT THERAPEUTICS, INC. Operating Cash Flow
PLIANT THERAPEUTICS, INC. (PLRX) reported Operating Cash Flow of -$32.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$12.80M.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$19.23M.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$17.79M.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$21.08M.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$128.34M.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$155.50M.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$116.36M.
- PLIANT THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$94.63M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$32.03M 10-Q · filed 2026-08-11 | -$49.81M derived: sum of 3 quarters · filed 2026-08-11 | -$70.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$19.23M 10-Q · filed 2026-05-11 | -$37.02M derived: sum of 2 quarters · filed 2026-05-11 | -$58.10M derived: sum of 3 quarters · filed 2026-05-11 | -$98.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$17.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$38.87M derived: sum of 2 quarters · filed 2026-03-11 | -$79.47M derived: sum of 3 quarters · filed 2026-08-11 | -$128.34M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$21.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$61.68M derived: sum of 2 quarters · filed 2026-08-11 | -$110.55M 10-Q · filed 2025-11-06 | -$158.21M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$40.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$89.47M 10-Q · filed 2026-08-11 | -$137.13M derived: sum of 3 quarters · filed 2026-08-11 | -$169.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$48.86M 10-Q · filed 2026-05-11 | -$96.53M derived: sum of 2 quarters · filed 2026-05-11 | -$128.80M derived: sum of 3 quarters · filed 2026-05-11 | -$174.10M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$47.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$79.94M derived: sum of 2 quarters · filed 2026-03-11 | -$125.23M derived: sum of 3 quarters · filed 2026-03-11 | -$155.50M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$32.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$77.57M derived: sum of 2 quarters · filed 2025-11-06 | -$107.84M 10-Q · filed 2025-11-06 | -$132.94M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$45.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$75.57M 10-Q · filed 2025-08-07 | -$100.67M derived: sum of 3 quarters · filed 2025-08-07 | -$136.89M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$30.27M 10-Q · filed 2025-05-08 | -$55.37M derived: sum of 2 quarters · filed 2025-05-08 | -$91.60M derived: sum of 3 quarters · filed 2025-05-08 | -$116.36M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$25.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$61.33M derived: sum of 2 quarters · filed 2025-03-03 | -$86.08M derived: sum of 3 quarters · filed 2025-03-03 | -$116.36M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$36.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$60.98M derived: sum of 2 quarters · filed 2024-11-07 | -$91.26M 10-Q · filed 2024-11-07 | -$122.50M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$24.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$55.03M 10-Q · filed 2024-08-07 | -$86.27M derived: sum of 3 quarters · filed 2025-03-03 | -$104.77M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$30.28M 10-Q · filed 2024-05-06 | -$61.52M derived: sum of 2 quarters · filed 2025-03-03 | -$80.01M derived: sum of 3 quarters · filed 2025-03-03 | -$104.41M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$31.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$49.74M derived: sum of 2 quarters · filed 2025-03-03 | -$74.13M derived: sum of 3 quarters · filed 2025-03-03 | -$94.63M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$18.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$42.89M derived: sum of 2 quarters · filed 2023-11-09 | -$63.39M 10-Q · filed 2023-11-09 | -$83.26M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$24.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$44.89M 10-Q · filed 2023-08-09 | -$64.76M derived: sum of 3 quarters · filed 2024-02-27 | -$87.27M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$20.50M 10-Q · filed 2023-05-09 | -$40.36M derived: sum of 2 quarters · filed 2024-02-27 | -$62.87M derived: sum of 3 quarters · filed 2024-02-27 | -$82.28M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$19.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$42.38M derived: sum of 2 quarters · filed 2024-02-27 | -$61.78M derived: sum of 3 quarters · filed 2024-02-27 | -$75.44M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$22.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$41.91M derived: sum of 2 quarters · filed 2022-11-08 | -$55.58M 10-Q · filed 2022-11-08 | -$72.06M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$19.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$33.07M 10-Q · filed 2022-08-08 | -$49.55M derived: sum of 3 quarters · filed 2022-08-08 | -$65.34M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$13.66M 10-Q · filed 2022-05-09 | -$30.15M derived: sum of 2 quarters · filed 2022-05-09 | -$45.94M derived: sum of 3 quarters · filed 2022-05-09 | -$38.17M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$16.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$32.28M derived: sum of 2 quarters · filed 2022-03-01 | -$24.50M derived: sum of 3 quarters · filed 2022-03-01 | -$37.27M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$15.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$8.02M derived: sum of 2 quarters · filed 2021-11-09 | -$20.79M 10-Q · filed 2021-11-09 | $15.96M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $7.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$4.99M 10-Q · filed 2021-08-09 | $31.75M derived: sum of 3 quarters · filed 2022-03-01 | $16.87M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$12.77M 10-Q · filed 2021-05-10 | $23.98M derived: sum of 2 quarters · filed 2022-03-01 | $9.10M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $36.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $21.87M derived: sum of 2 quarters · filed 2022-03-01 | -$2.75M 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$14.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$39.49M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$24.62M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |